A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02667873. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT02667873
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- SL-801 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 22, 2016
- Primary completion
- Oct 5, 2021
- Completion
- Oct 12, 2021
- Last update posted
- Feb 9, 2025
2016 – 2021
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Florida Cancer Specialist | Sarasota | Florida | 34236 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Mary Crowely Cancer Research Centers- Medical City | Dallas | Texas | 75230 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| University of Washington, Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02667873, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02667873 live on ClinicalTrials.gov.